Ms Lufkin and Mr. O'Meara own stock or stock options in Synta Pharmaceuticals.
Brief Report: A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis†
Version of Record online: 25 MAY 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 64, Issue 6, pages 1750–1755, June 2012
How to Cite
Krausz, S., Boumans, M. J. H., Gerlag, D. M., Lufkin, J., van Kuijk, A. W. R., Bakker, A., de Boer, M., Lodde, B. M., Reedquist, K. A., Jacobson, E. W., O'Meara, M. and Tak, P. P. (2012), Brief Report: A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. Arthritis & Rheumatism, 64: 1750–1755. doi: 10.1002/art.34339
ClinicalTrials.gov identifier: NCT00642629.
- Issue online: 25 MAY 2012
- Version of Record online: 25 MAY 2012
- Accepted manuscript online: 14 DEC 2011 12:22PM EST
- Manuscript Accepted: 8 DEC 2011
- Manuscript Received: 29 APR 2011
- Synta Pharmaceuticals
Additional Supporting Information may be found in the online version of this article.
|ART_34339_sm_SupplFig1.TIF||118K||Supplementary Figure 1|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.